Portola Pharma (PTLA) Misses Q1 EPS by 9c

Portola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $7.91 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business